Am J Nurs. 2022 May 1;122(5):49. doi: 10.1097/01.NAJ.0000830760.52646.d9.
According to this study: Among patients younger than 21 years of age who have provoked venous thromboembolism, anticoagulant therapy for six weeks compared with three months met noninferiority criteria based on the trade-off between recurrent venous thromboembolism risk and bleeding risk.
在年龄小于 21 岁且有诱因的静脉血栓栓塞症患者中,与抗凝治疗 3 个月相比,抗凝治疗 6 周在复发静脉血栓栓塞症风险与出血风险之间达到了非劣效性标准。